4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8,508,900.00% | 2,900.00% | 200.00% | -50.00% | 105.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,508,900.00% | 2,900.00% | 200.00% | -50.00% | 105.26% |
| Cost of Revenue | 33.47% | 22.75% | 50.51% | 46.03% | 65.54% |
| Gross Profit | 164.02% | -22.52% | -50.48% | -46.13% | -65.42% |
| SG&A Expenses | -2.03% | -6.43% | 8.67% | 25.67% | 22.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.23% | 15.53% | 40.06% | 40.54% | 53.19% |
| Operating Income | 126.40% | -15.36% | -40.04% | -40.60% | -53.11% |
| Income Before Tax | 139.05% | -29.73% | -56.38% | -48.06% | -53.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 139.05% | -29.73% | -56.38% | -48.06% | -53.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 139.05% | -29.73% | -56.38% | -48.06% | -53.86% |
| EBIT | 126.40% | -15.36% | -40.04% | -40.60% | -53.11% |
| EBITDA | 129.14% | -15.58% | -41.27% | -42.22% | -54.77% |
| EPS Basic | 134.00% | -28.41% | -54.56% | -30.87% | -18.54% |
| Normalized Basic EPS | 134.16% | -23.44% | -54.55% | -30.88% | -18.53% |
| EPS Diluted | 134.00% | -28.41% | -54.56% | -30.87% | -18.54% |
| Normalized Diluted EPS | 134.16% | -23.44% | -54.55% | -30.88% | -18.53% |
| Average Basic Shares Outstanding | 14.88% | 1.03% | 1.17% | 13.14% | 29.80% |
| Average Diluted Shares Outstanding | 14.88% | 1.03% | 1.17% | 13.14% | 29.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |